Evidence map›Paper›PMID 31527170›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma.

Yi Qin, Chung W Wu, William R Taylor, Tarek Sawas, Kelli N Burger, Douglas W Mahoney, Zhifu Sun, Tracy C Yab, Graham P Lidgard, Hatim T Allawi and 6 more

Registry-linked trialOpen access · bronzeAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05680077 (Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions), which is not on this map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05680077 completednot on this mapstarted 2022, after this paper: background citation

Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions: a Clinical Trial

Typeobservational_patient_registrySponsorWuhan Ammunition Life-tech Co., LtdRan2022 to 2023Enrolled1,116ConditionsEsophageal NeoplasmsArmsKCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yi QinGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3326-1640
Chung W WuGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
William R TaylorGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Tarek SawasGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Kelli N BurgerBiomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Douglas W MahoneyBiomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Zhifu SunBiomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Tracy C YabGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Graham P LidgardExact Sciences Development Company, Madison, Wisconsin.
Hatim T AllawiExact Sciences Development Company, Madison, Wisconsin.
Navtej S ButtarGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Thomas C SmyrkGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Prasad G IyerGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
David A KatzkaGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
David A AhlquistGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
John B KisielGastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. kisiel.john@mayo.edu.ORCID 0000-0002-3840-5324
Mayo Clinic · USExact Sciences (United States) · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Mayo Clinic Center for Translational Science ActivitiesKL2TR000136 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$6.6M
Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
NCATS NIH HHS KL2 TR000136NCATS NIH HHS UL1 TR002377NCI NIH HHS R37 CA214679NCI NIH HHS U54 CA163060
6 · The paper itself

Abstract

purposeThe burden of esophageal cancer continues to rise, and noninvasive screening tools are needed. Methylated DNA markers (MDM) assayed from plasma show promise in detection of other cancers. For esophageal cancer detection, we aimed to discover and validate MDMs in tissue, and determine their feasibility when assayed from plasma. EXPERIMENTAL

designWhole-methylome sequencing was performed on DNA extracted from 37 tissues (28 EC; 9 normal esophagus) and 8 buffy coat samples. Top MDMs were validated by methylation specific PCR on tissue from 76 EC (41 adeno, 35 squamous cell) and 17 normal esophagus. Quantitative allele-specific real-time target and signal amplification was used to assay MDMs in plasma from 183 patients (85 EC, 98 controls). Recursive partitioning (rPART) identified MDM combinations predictive of esophageal cancer. Validation was performed

resultsFrom discovery, 23 candidate MDMs were selected for independent tissue validation; median area under the receiver operating curve (AUC) for individual MDMs was 0.93. Among 12 MDMs advanced to plasma testing, rPART modeling selected a 5 MDM panel (

conclusionsNovel MDMs assayed from plasma detect esophageal cancer with moderate accuracy. Further optimization and clinical testing are warranted.

Indexed as

DNA MethylationEpigenomeAgedBiomarkers, TumorCase-Control StudiesEarly Detection of CancerEsophageal NeoplasmsFemaleHumansMaleMiddle AgedRho Guanine Nucleotide Exchange FactorsROC CurveSialyltransferasesT-Box Domain ProteinsTumor Suppressor Proteinsalpha-N-acetylneuraminate alpha-2,8-sialyltransferaseARHGEF4 protein, humanBiomarkers, TumorRho Guanine Nucleotide Exchange FactorsSialyltransferasesT-Box Domain ProteinsTBX15 protein, humanTumor Suppressor ProteinsZNF671 protein, human

Identifiers

PMID31527170
PMCPMC6911634
OpenAlexW2974813020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.